Status:
COMPLETED
Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Diabetes
Eligibility:
All Genders
25-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes patients with inadequate control of blood glucose with diet and/or exercise therapy
Exclusion Criteria:
- Type 1 diabetes patients
- Patients who require treatment with insulin
- Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)
- Patients with severe ketosis, diabetic coma or precoma
- Patients complicated with severe hepatic diseases
- Patients complicated with severe renal diseases
- Patients complicated with severe hypertension
- Patients complicated with severe cardiac disease
- Pregnant women or women possible to be pregnant, nursing women, or women who want to become pregnant during the study period
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
291 Patients enrolled
Trial Details
Trial ID
NCT00461617
Start Date
August 1 2006
End Date
July 1 2007
Last Update
October 21 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.